Clene Company Leadership
| CLNN Stock | USD 3.66 0.08 2.14% |
Clene employs about 75 people. The company is managed by 10 executives with a total tenure of roughly 175 years, averaging almost 17.0 years of service per executive, having 7.5 employees per reported executive. Analysis of Clene's management performance can provide insight into the firm performance.
Clene Management Team Effectiveness
The company has return on total asset (ROA) of (0.4962) % which means that it has lost $0.4962 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.3836) %, meaning that it created substantial loss on money invested by shareholders. Clene's management efficiency ratios could be used to measure how well Clene manages its routine affairs as well as how well it operates its assets and liabilities.Clene Workforce Comparison
Clene Inc is rated second in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 424. Clene retains roughly 75.0 in number of employees claiming about 18% of equities under Health Care industry.
Clene Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clene insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Clene insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Clene Notable Stakeholders
A Clene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Clene often face trade-offs trying to please all of them. Clene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Clene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert MBA | President CEO | Profile | |
| Robert MD | Chief Officer | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Tae Mgt | Consultant | Profile | |
| Mark ESQ | Chief Officer | Profile | |
| Michael Hotchkin | Chief Officer | Profile | |
| Mark Mortenson | CoFounder Officer | Profile | |
| Mary Mcneil | Head Resources | Profile | |
| MHS MD | Head Medical | Profile | |
| Jerry JD | General Secretary | Profile |
About Clene Management Performance
The success or failure of an entity such as Clene Inc often depends on how effective the management is. Clene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Clene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Clene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 95 people.
Clene Workforce Analysis
Traditionally, organizations such as Clene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Clene within its industry.Clene Manpower Efficiency
Return on Clene Manpower
| Revenue Per Employee | 4.6K | |
| Revenue Per Executive | 34.2K | |
| Net Loss Per Employee | 525.3K | |
| Net Loss Per Executive | 3.9M | |
| Working Capital Per Employee | 78.2K | |
| Working Capital Per Executive | 586.6K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clene Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.